Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | PLD1 | Q13393 | 6/20 | 0.42 |
| ▸ | TNKS | O95271 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.41 |
| ▸ | PLD2 | O14939 | 5/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4440103 | 0.90 | CTSS (0.42) | CTSSHTR1AADRA2ADRD2HTR2A | |
| SCHEMBL5000779 | 0.88 | HTR1A (0.41) | CTSSHTR1AADRA2ADRD2HTR2A | |
| SCHEMBL4446685 | 0.86 | CTSS (0.45) | CTSSHTR1AADRA2ADRD2HTR2A | |
| SCHEMBL4436328 | 0.81 | PLD1 (0.51) | CTSSHTR1AADRA2ADRD2HTR2A | |
| SCHEMBL4435644 | 0.80 | CCR5 (0.46) | CTSSHTR1AHSD11B1 | |
| SCHEMBL4438969 | 0.78 | YEATS4 (0.53) | DRD2PLD1PLD2HSD11B1 | |
| SCHEMBL14146550 | 0.77 | YEATS4 (0.65) | DRD2PLD1PLD2 | |
| SCHEMBL4436430 | 0.76 | CTSS (0.44) | CTSSHTR1AADRA2ADRD2HTR2A | |
| SCHEMBL4435623 | 0.76 | PLD2 (0.39) | PLD1TNKSPARP1PARP2PLD2 | |
| SCHEMBL4434717 | 0.76 | YEATS4 (0.61) | CTSSHTR1AADRA2ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | claimed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | claimed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | SPTLC1, SPTLC2, CPT1A | CTSS 667/4885HTR1A 2156/4885ADRA2A 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.